Biosimilar Development News

  1. FDA Approves Amgen And Allergan's KANJINTI™ (Trastuzumab-anns), A Biosimilar To Herceptin® (Trastuzumab)
    6/14/2019

    Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

  2. Psoriasis Treatment Market To Gain US$12.1B; Introduction Of Biosimilars To Accelerate Industry Growth, Says TMR
    6/12/2019

    As reported by TMR, the global psoriasis treatment market is prognosticated to exhibit a 5.10% CAGR over the forecast period from 2016 to 2024. The market was estimated to be worth US$7.8 bn in 2015 and is forecasted to reach US$12.1 bn by 2024.

  3. Advisory Council On The Implementation Of National Pharmacare Highlights Importance Of Biosimilar Medicines
    6/12/2019

    The Advisory Council on the Implementation of National Pharmacare’s Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.

  4. Advisory Panel On The Implementation Of National Pharmacare Highlights Importance Of Biosimilar Medicines
    6/12/2019

    The Advisory Council on the Implementation of National Pharmacare's Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.1

  5. New Subcutaneous Formulation Of Celltrion Healthcare’s CT-P13 (Biosimilar Infliximab) Shows Positive Results For The Treatment Of Rheumatoid Arthritis (RA) In Data Presented At The Annual European Congress Of Rheumatology (EULAR 2019)
    6/11/2019

    Celltrion Healthcare recently presented new findings at the Annual European Congress of Rheumatology (EULAR 2019) from a two-part study investigating the pharmacokinetics, efficacy and overall safety of CT-P13 SC in patients with RA during the treatment period of one year.

  6. Biogen To Present New Safety And Efficacy Data On Biosimilars And Estimates 1.8 Billion Euros In Savings For The European Healthcare System In 2019
    6/11/2019

    Biogen Inc. (Nasdaq: BIIB) today announced that it will present new data at the European Congress of Rheumatology (EULAR) 2019 in Madrid, Spain (June 12-15). The abstracts include real-world data from the company’s biosimilar anti-TNF portfolio, which includes BENEPALI™ (etanercept), FLIXABI™ (infliximab) and IMRALDI™ (adalimumab).

  7. Patients, Physicians Raise Concerns With BC Biosimilar Non-Medical Switching Policy
    6/6/2019

    On May 27th, the Government of British Columbia (B.C.) announced a policy that will forcibly switch thousands of patients with serious, chronic conditions from their current biologic medicines to lower-cost "biosimilar" treatments, effective November 25th, 2019.

  8. Pfizer To Launch Several Drugs Despite Generic Headwinds
    6/5/2019

    Pfizer, Inc. PFE expects continued strong growth of key product franchises, including Ibrance, Eliquis, Xeljanz and Prevnar.

  9. Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus®
    6/5/2019

    Lannett Company, Inc. (NYSE: LCI) today announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC).

  10. Magellan Rx Management Launches Oncology Biosimilar Medical Pharmacy Solution, Aims To Improve Member Access, Reduce Costs And Save Customers Millions In Drug Spend
    6/4/2019

    Magellan Rx Management, the pharmacy benefit management (PBM) division of Magellan Health, Inc., recently announced the launch of a medical pharmacy solution targeting oncology therapeutic biosimilars.